Taysha Gene Therapies, Inc. TSHA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -1,774.4%-549pp | -1,130.6%-33.1pp | -1,618.5%-733pp | -1,160.8%-554pp | -1,225.8%-659pp | |
| Net margin | -1,738.4%-537pp | -1,115.3%-43.6pp | -1,583.7%— | -1,145%— | -1,201.1%— | |
| EBITDA margin | -1,759.7%-550pp | -1,119.6%-36.8pp | -1,601.3%-729pp | -1,146.2%-549pp | -1,209.3%-653pp | |
| Free cash flow margin | -1,503.6%-340pp | -960.1%+19.2pp | -1,349.6%-549pp | -1,019.2%-431pp | -1,163.6%-650pp | |
| Returns | ||||||
| Return on equity | -97.3%+62.1pp | -68.5%+53.5pp | -64.9%— | -51.9%— | -159.3%— | |
| Return on assets | -59.2%+0.4pp | -43.3%+10.3pp | -40.2%— | -34.7%— | -59.6%— | |
| Return on invested capital | -6,605%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | 0×-0.1× | |
| Liquidity | ||||||
| Current ratio | 14×+8.7× | 12.2×+6.8× | 10.5×+5.0× | 12.5×+7.3× | 5.4×+2.0× | |
| Quick ratio | 14×+8.7× | 12.2×+6.8× | 10.5×+5.0× | 12.5×+7.3× | 5.4×+2.0× | |
| Cash ratio | 13.8×+8.6× | 12×+6.7× | 10.4×+5.0× | 12.3×+7.3× | 5.2×+2.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×-0.8× | 0.3×-0.6× | 0.3×-0.4× | 0.2×-0.3× | 1.1×0.0× | |
| Debt-to-assets | 0.2×-0.2× | 0.2×-0.2× | 0.2×-0.1× | 0.2×-0.1× | 0.4×0.0× | |
| Interest coverage | -2,501.2×-1,539× | -1,753.9×-857× | -1,399×-1,288× | -1,146.4×-1,112× | -962.5×-941× | |
| Per Share | ||||||
| Book value per share | $0.58+183% | $0.77+170% | $0.62+87.0% | $0.83+78.5% | $0.20-12.2% | |
| Valuation | ||||||
| Market capitalization | $1.28B+351% | $1.51B+325% | $892.04M+119% | $619.83M+36.5% | $284.95M-50.7% | |
| Enterprise value | $1.08B+368% | $1.26B+350% | $663.78M+112% | $366.83M+8.0% | $229.99M-55.4% | |
| Price / sales | 171.9×+132× | 154.2×+112× | 141.4×+100× | 76.5×+41.3× | 39.4×-1.4× | |
| Price / book | 6.1×+0.9× | 6.1×+1.1× | 4.1×-0.5× | 2.5×-1.7× | 5.2×-5.6× | |
| EV / sales | 144×+112× | 128.6×+95.1× | 105.2×+73.6× | 45.3×+18.9× | 31.8×-4.6× | |
| Free cash flow yield | -8.7%+20.8pp | -6.2%+16.8pp | -9.5%+9.9pp | -13.3%+3.4pp | -29.5%-16.9pp | |
| Earnings yield | -10.1%+20.3pp | -7.2%+18.0pp | -11.2%— | -15%— | -30.4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Taysha Gene Therapies, Inc.'s ratios come from?
- Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
